Targeting triple negative breast cancer stem cells using nanocarriers
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Triple-negative breast cancer (TNBC) is aggressive and hard to treat. Nanoparticle therapies show promise for targeting cancer stem cells in TNBC, potentially improving patient outcomes.
Area Of Science
- Oncology
- Nanomedicine
- Cancer Biology
Background
- Breast cancer is heterogeneous, with subtypes like triple-negative breast cancer (TNBC) lacking ER, PR, and HER2 receptors.
- TNBC exhibits aggressive behavior, high recurrence rates, and resistance to conventional therapies.
- Breast cancer stem cells (BCSCs) drive TNBC initiation, progression, and treatment resistance.
Purpose Of The Study
- To review nanoparticle-based therapeutic strategies for targeting BCSCs in TNBC.
- To address challenges in BCSC-targeted therapy, including off-target effects and poor bioavailability.
- To explore how nanocarriers can improve TNBC treatment efficacy and reduce systemic toxicity.
Main Methods
- Review of current literature on BCSCs in TNBC.
- Analysis of various nanocarrier systems and their applications in targeting TNBC BCSCs.
- Discussion of key molecular targets within BCSCs, including self-renewal pathways and survival proteins.
Main Results
- BCSCs are critical targets for effective TNBC treatment.
- Nanoparticle-based therapies offer a viable approach to overcome limitations of conventional BCSC-targeting agents.
- Targeting BCSCs via nanocarriers can enhance drug delivery, minimize toxicity, and improve therapeutic outcomes.
Conclusions
- Nanoparticle-based strategies represent a promising avenue for overcoming therapeutic challenges in TNBC.
- Targeted delivery to BCSCs using nanocarriers holds potential for improving survival rates and reducing recurrence in TNBC patients.
- Further research into nanocarrier design and BCSC targeting is crucial for advancing TNBC treatment.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...